Becker’s Healthcare Podcast Dhruv Bansal, MD, MBA, Director of Immunotherapy, Precision and Thoracic Oncology at Endeavor Health
Dec 24, 2025
Dr. Dhruv Bansal, an expert in immunotherapy and precision oncology at Endeavor Health, delves into the groundbreaking advancements in cancer treatment. He discusses how precision medicine is bridging genomic research and clinical practice. Notably, he explores why some stage 4 lung cancer patients achieve impressive survival rates, the transformative impact of targeted therapies, and the future role of mRNA vaccines in cancer care. Bansal emphasizes the exciting potential of cellular therapies and collaborative projects combining clinical data with AI to enhance treatment outcomes.
AI Snips
Chapters
Transcript
Episode notes
Long-Term Survivors Are Now Common
- Some stage 4 lung cancer patients now survive five to ten years or more due to new therapies.
- Dhruv Bansal, MD researches why a subset of patients achieve long-term remission.
Precision Medicine Changed Cancer Care
- Precision medicine has transformed oncology from chemo-first to targeted therapies with fewer side effects.
- Dhruv Bansal, MD says targeted treatments are more effective and gentler than chemotherapy for many lung cancer patients.
Keep Up Through Continuous Learning
- Stay current by reading key journals and attending major conferences regularly.
- Dhruv Bansal, MD also recommends active peer interaction and conducting research to translate discoveries into practice.